Idexx Laboratories reports Q1 EPS $3.47, consensus $3.41

Reports Q1 revenue $1.14B, consensus $1.11B. “Excellent commercial execution delivered exceptional first quarter results and positions IDEXX for continued strength through 2026,” said Jay Mazelsky, President and Chief Executive Officer. “IDEXX Cancer Dx platform momentum continues to build with the recent International launch and growing adoption in the U.S., and our IDEXX inVue Dx roll-out further advances our innovation-driven growth strategy. Initial customer response to the controlled launch of IDEXX inVue Dx FNA has been very encouraging and supports broadening access over the remainder of the year. As I transition from the CEO role, IDEXX remains well-positioned for continued success, and I look forward to continuing to work with Mike Erickson to drive long-term sustained growth in the business.”